Dashboard
Manage Tickers

VIR Vir Biotechnology, Inc.

Nasdaq vir.bio


$ 5.80 $ -0.34 (-5.56 %)    

Thursday, 23-Oct-2025 16:08:30 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 613.72 $ 0.00 (0 %)
DIA $ 467.90 $ 0.00 (0 %)
SPY $ 673.83 $ 0.00 (0 %)
TLT $ 91.37 $ 0.00 (0 %)
GLD $ 374.47 $ 0.00 (0 %)
$ 5.78
$ 6.09
$ 5.50 x 10
$ 6.50 x 340
-- - --
$ 4.16 - $ 14.45
4,663,286
na
802.94M
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-26-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 02-26-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-11-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
24 11-19-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

vir-biotechnology-doses-first-patient-in-phase-1-trial-of-dual-masked-t-cell-engager-vir-5500-for-prostate-cancer
Vir Biotechnology Doses First Patient In P...
10/09/2025 20:09:52

– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination wi...

hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Vir ...
09/15/2025 18:39:57

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $15 p...

evercore-isi-group-initiates-coverage-on-vir-biotechnology-with-outperform-rating-announces-price-target-of-12
Evercore ISI Group Initiates Coverage On V...
09/03/2025 13:34:49

Evercore ISI Group analyst Cory Kasimov initiates coverage on Vir Biotechnology (NASDAQ:VIR) with a Outperform rating and an...

this-astera-labs-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-friday
This Astera Labs Analyst Begins Coverage O...
08/29/2025 17:37:09

this-southwest-gas-analyst-turns-bullish-here-are-top-2-upgrades-for-friday
This Southwest Gas Analyst Turns Bullish; ...
08/29/2025 17:35:23

this-oddity-tech-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Oddity Tech Analyst Begins Coverage O...
08/28/2025 12:43:21

this-guess-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday
This Guess Analyst Is No Longer Bullish; H...
08/28/2025 12:39:49

this-eli-lilly-analyst-is-no-longer-bearish-here-are-top-4-upgrades-for-wednesday
This Eli Lilly Analyst Is No Longer Bearis...
08/27/2025 17:49:31

b-of-a-securities-upgrades-vir-biotechnology-to-buy-raises-price-target-to-14
B of A Securities Upgrades Vir Biotechnolo...
08/27/2025 15:49:42

B of A Securities analyst Geoff Meacham upgrades Vir Biotechnology (NASDAQ:VIR) from Neutral to Buy and raises the price tar...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/27/2025 12:08:39

vir-biotechnology-q2-eps-080-misses-076-estimate-sales-121m-miss-238m-estimate
Vir Biotechnology Q2 EPS $(0.80) Misses $(...
08/06/2025 20:10:20

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(...

vir-biotechnology-launches-final-eclipse-trial-advancing-full-registrational-program-for-chronic-hepatitis-delta
Vir Biotechnology Launches Final ECLIPSE T...
08/06/2025 12:17:32

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3ECLIPSE 3 is designed ...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

vir-biotechnology-enrolls-first-participant-in-eclipse-2-phase-3-trial-for-chronic-hepatitis-delta
Vir Biotechnology Enrolls First Participan...
07/31/2025 12:08:50

vir-biotechnology-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-vir-5525-investigational-dual-masked-t-cell-engager-targeting-egfr
Vir Biotechnology Announces First Patient ...
07/24/2025 12:08:37

Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combina...

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
07/11/2025 21:06:01

where-vir-biotechnology-stands-with-analysts
Where Vir Biotechnology Stands With Analysts
07/11/2025 14:01:10

raymond-james-initiates-coverage-on-vir-biotechnology-with-outperform-rating-announces-price-target-of-12
Raymond James Initiates Coverage On Vir Bi...
07/11/2025 13:04:32

Raymond James analyst Sean McCutcheon initiates coverage on Vir Biotechnology (NASDAQ:VIR) with a Outperform rating and anno...

vir-biotechnology-stock-a-deep-dive-into-analyst-perspectives-6-ratings
Vir Biotechnology Stock: A Deep Dive Into ...
05/22/2025 12:01:31

needham-reiterates-buy-on-vir-biotechnology-maintains-14-price-target
Needham Reiterates Buy on Vir Biotechnolog...
05/22/2025 10:32:58

Needham analyst Joseph Stringer reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $14 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION